Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
hMSC Infusion for Anti-Aging
NCT04174898Phase 1Unknown
- Sponsor
- Landmark Medical Center
- Start
- Apr 2020
- Primary completion
- Apr 2021
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of human mesenchymal stem cells in aging, sponsored by Landmark Medical Center. Primary endpoints: Number of Participants with Treatment-Related Adverse Events at 1 year, Improvement in General Well-Being at 1 year and 1 more. Status: unknown.
02
Drugs
human mesenchymal stem cells
03
Conditions
aging
Beyond the preview
Go deeper on NCT04174898.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04174898.